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High blood pressure (BP) is the leading risk factor for car-diovascular disease worldwide.1 Systolic BP (SBP) and 
diastolic BP (DBP) are complex physiological traits that are 
affected by both genetic and environmental factors.2,3 Recently, 
2 genome-wide gene expression studies on peripheral leuko-
cytes identified 40 genes that were differentially expressed in 
relation to BP.4,5 However, the causal nature of these associa-
tions remains unclear. In addition to the possibility of 1-way 
causation, their relationships can also be bidirectional. For 
example, the cellular processes underlying BP regulation may 
result in changes in gene expression. In turn, the gene expres-
sion or its downstream molecular products may increase the 
risk of hypertension. It is also possible that common genetic 
effects account for the observed associations between BP and 
gene expression. Similar to BP, the expression level of a gene 
is determined by both genetic and environmental factors,6 
although the extent to which the BP-related gene expression 
signatures are driven by genetic factors has not been investi-
gated. Discovery of a common genetic substrate may point 
toward a common pathogenic pathway and improve our under-
standing of the molecular mechanisms underlying BP regula-
tion. In the present study of a transcriptome-wide analysis in 
leukocytes from 391 adult twins, we first identified new tran-
scriptional signals associated with BP, next replicated previous 
signals associated with BP, third conducted twin modeling to 
estimate the heritability of gene expression signatures of BP, 
and finally assessed whether shared genetic effects play a role 
in the link between BP and gene expression.
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Abstract—Recently, 2 transcriptome-wide studies identified 40 genes that were differentially expressed in relation to blood 
pressure. However, to what extent these BP-related gene expression signatures and their associations with BP are driven by 
genetic or environmental factors has not been investigated. In this study of 391 twins (193 twin pairs and 5 singletons; age 
55–69 years; 40% male; 57% monozygous) recruited from the Finnish Twin Cohort, transcriptome-wide data on peripheral 
leukocytes were obtained using the Illumina HT12 V4 array. Our transcriptome-wide analysis identified 1 gene (MOK 
[MAPK/MAK/MRK overlapping kinase], P=7.16×10−8) with its expression levels associated with systolic BP at the cutoff 
of false-discovery rate <0.05. This association was further replicated in the Framingham Heart Study (P=1.02×10−5). Out 
of the 40 genes previously reported, 12 genes could be replicated in the twin cohort with false-discovery rate <0.05 and 
consistent direction of effect. Univariate twin modeling showed that genetic factors contributed to the expression variations 
of 12 genes with heritability estimates ranging from 6% to 65%. Bivariate twin modeling showed that 53% of the phenotypic 
association between systolic BP and MOK expression, and 100% of the phenotypic association of systolic and diastolic BP 
with CD97 (cluster of differentiation 97), TIPARP (TCDD-inducible poly[ADP-ribose] polymerase), and TPPP3 expression 
could be explained by genetic factors shared in common. In this study of adult twins, we identified one more gene, MOK, with 
its expression level associated with BP, and replicated several previously identified signals. Our study further provides 
new insights into the genetic and environmental sources of BP-related gene expression signatures.  (Hypertension. 
2018;71:457-464. DOI: 10.1161/HYPERTENSIONAHA.117.10527.) • Online Data Supplement
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Methods
The data that support the findings of this study are available from the 
corresponding author on reasonable request.
Subjects
In 2011, a comprehensive questionnaire was sent to all the living 
twins of the Finnish Twin Cohort born between 1945 and 1957 
(11 738 twins). A total of 8501 twins returned the questionnaire 
with a response rate of 72%.7 Three questions in this questionnaire 
are related to hypertension: (1) When was your BP last measured? 
(2) Have you ever been told that you have elevated BP or hyperten-
sion? and (3) On how many days in the past year have you used 
antihypertensive medication? On the basis of the questionnaire, 
twins were defined as hypertensive if they had been diagnosed with 
hypertension or had taken antihypertensive medication for at least 
2 months, whereas twins were defined as normotensive if they had 
not been diagnosed with hypertension and did not take antihyper-
tensive medication. On the basis of the replies, 330 same-sex twin 
pairs free of self-reported previous diagnosis of myocardial infarc-
tion, congestive heart failure, or stroke were defined as poten-
tially discordant for hypertension. These twin pairs were phone 
interviewed and asked to participate in clinical assessments at the 
University of Helsinki during 2012 to 2015. A total of 222 twin 
pairs and 3 singletons (n=447) participated in the clinical protocol. 
Informed consent was obtained from each subject, and the study 
was approved by the Ethics Committee of the University Central 
Hospital of Helsinki.
Measurements
During the clinical testing, the twins had a comprehensive physical 
examination, and their health history was recorded, including ques-
tions again about previous diagnoses of hypertension and use of anti-
hypertensive medication. Resting BPs were measured 4 times during 
the visit, seated by a sphygmomanometer according to the JNC7 
guidelines (Seventh Joint National Committee). The average of the 
last 2 readings of each measurement occasion was used to represent 
BP values. Information on medications was further complemented 
with data from community pharmacies. On the basis of the fact that 
only 50 twin pairs met the criteria for current discordance for hyper-
tension (1 twin on antihypertensive medication or with SBP ≥140 
mm Hg or DBP ≥90 mm Hg and his/her cotwin not on antihyperten-
sive medication and with SBP <120 mm Hg and DBP <80 mm Hg), 
we included all the twins for the current analysis by using SBP and 
DBP as continuous variables. If antihypertensive medication was 
used, 15 and 10 mm Hg were added to the measured SBP and DBP 
levels, respectively.8 Fasting peripheral blood samples were obtained 
from 402 participants. Zygosity was determined by genotyping using 
Illumina HumanCoreExome BeadChip.
RNA Extraction and Transcriptome-Wide Gene 
Expression Assays
RNA samples were extracted from the peripheral leukocytes stored in 
the RNA cell protection reagents (Qiagen, Inc, Valencia, CA) using the 
miRNeasy Mini Kit (Qiagen, Inc). RNA concentration and purity were 
evaluated on a NanoDrop spectrophotometer 2000 (Thermo Scientific, 
Inc, Waltham, MA). RNA integrity was evaluated on a Bioanalyzer 
2100 (Agilent, Inc, Santa Clara, CA), and samples with a RNA integ-
rity score ≥8 qualified for gene expression analysis. Out of the 402 
peripheral blood samples, high-quality RNA was obtained for 391 sub-
jects (116 monozygotic, 77 dizygotic twin pairs, and 5 singletons).
Transcriptome-wide gene expression data were obtained using 
the Illumina HumanHT-12 v4 Expression BeadChip (Illumina, 
Inc, San Diego, CA). This chip targets >48 000 probes that pro-
vide transcriptome-wide coverage of well-characterized genes, 
gene candidates, and splice variants. A block design was used to 
keep the distributions of sex and zygosity similar across chips (12 
samples/chip) with the cotwins assigned to the same chip. The 
twin pairs were randomly assigned to the 12 positions on each 
chip. The Genome-Studio Gene Expression Module (Illumina) 
was used for initial quantification and the lumi package9 for data 
preprocessing and quality control, which included the following 
key steps: (1) probes with detection P value <0.05 in >50% of 
the samples were defined as present; (2) log2 transformation and 
quantile normalization were applied to the gene expression data. 
There were 19 530 probes that passed the quality control steps, 
and they were used as indices of gene expression levels in further 
analyses.
Statistical Analysis
The purposes of our analyses were (1) to identify novel and repli-
cate previously identified differentially expressed genes associated 
with BP in the Finnish twin cohort4,5; (2) to disentangle genetic and 
environmental sources of expression variation of the BP-associated 
genes; and (3) to test whether common genetic or environmental 
effects account for the observed association between BP and gene 
expression. We used linear mixed model to answer the first aim 
and structural equation modeling to answer the other 2 aims of 
our study.
Linear Mixed Model
In the entire sample treating twins as individuals, mixed-effect 
linear regression models with intercept varying among chips and 
varying among twin pairs within chips to account for the block 
design and the relatedness of twins were performed to examine 
the relationship between BP (explanatory variables) and gene 
expressions (outcome variables), adjusting for age, sex, and body 
mass index. The differentially expressed genes identified for BP 
with a false-discovery rate (FDR) <0.05 were carried forward for 
replication in the Framingham Heart Study5 (n=3679, 42% males, 
aged 51±12). RNA was isolated from whole-blood samples that 
were collected in PaxGene tubes (PreAnalytiX, Hombrechtikon, 
Switzerland), and the Affymetrix Exon Array ST 1.0 was used 
in the Framingham Heart Study. Replication was defined as con-
sistent direction of the β-coefficient and FDR <0.05. We also 
checked whether we could replicate any of the 40 genes identified 
by previous studies5,10 that showed association of their expression 
with BP. Replication was defined successful if the direction of the 
BP-associated gene expression (β-coefficient) was consistent and 
FDR <0.05.
Univariate Structural Equation Modeling
To estimate the relative contributions of genetic and environmen-
tal factors on the expression variation of the BP-associated genes, 
structural equation modeling was conducted using the R package 
OpenMx.11,12 Before analysis, age, sex, body mass index, and chip 
effects were regressed out, and the gene expression residuals were 
used in model fitting. The univariate model (Figure [A]) allows sep-
aration of the observed phenotypic variance into underlying addi-
tive genetic variance (A), common environmental variance shared 
by a twin pair (C), and unique environmental variance specific to 
individuals (E). Under this model, we assumed that the monozy-
gotic twins share 100% of their genes, whereas dizygotic twins 
share 50% of their segregating genes on average. We define shared 
environmental factors to be those that are the same effects on the 
cotwins irrespective of zygosity, whereas unique environmental fac-
tors are by definition not shared by the cotwins, whether monozy-
gotic or dizygotic. Significance tests of the individual path (A, C, 
or E) were conducted by constraining paths to zero and applying χ2 
test (P<0.05).
Bivariate Structural Equation Modeling
A bivariate Cholesky decomposition was used to model the cova-
riance between gene expression and BP. This model can deter-
mine to what extent the covariance can be explained by common 
genetic or environmental factors. Details of this model have been 
described previously.13 As shown in Figure [B], similar to the uni-
variate model, the variation of gene expression and the variation of 
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bivariate model allows determination of the sources of the observed 
covariance between gene expression and BP by using a sequence 
of models that testing which paths (a21 for genetic covariance, 
c21 for shared environmental covariance, or e21 for covariance of 
unshared environmental effects) can be set to 0. For example, if a21 
cannot be set to 0, it allows further determination of the amount of 
overlap between the genetic factors influencing gene expression 
and BP by calculating the genetic correlation between the traits: 
rg=COVA(gene expression and BP)/√(VA gene expression*VA BP). 
Shared and unique environmental correlations can be calculated in 
a similar fashion.
Functional Analysis
Gene set enrichment analysis14,15 was used to identify sets of genes 
representing biological processes and pathways associated with gene 
expression changes associated with BP. Gene set enrichment analy-
sis was performed on an unfiltered ranked lists of genes (ranked by 
the P values), and a running-sum statistic was used to determine the 
enrichment of a prior defined gene sets (pathways) based on the gene 
ranks. Statistical significance of pathway enrichment score was ascer-
tained by permutation testing over size-matched random gene sets, 
and multiple testing was controlled by FDR. An FDR <0.05 was con-
sidered as significant. We tested for enrichment of any gene ontology 
biological processes or KEGG (Kyoto Encyclopedia of Genes and 
Genomes) pathways.
Results
The general characteristics of participants are presented for 
all and by zygosity are presented in Table 1. We identified 1 
gene (MOK [MAPK/MAK/MRK overlapping kinase]) that 
was differentially expressed in relation to SBP (Table 2) 
at FDR <0.05. For this gene, higher expression was asso-
ciated with higher SBP levels. Similar association of this 
gene with DBP was also observed with a nominal P value 
of 1.34×10−5. Limiting the analysis to participants with 
no antihypertensive medication revealed the same results 
with higher MOK expression associated with higher BP 
levels (P=0.02 and 0.04 for SBP and DBP, respectively). 
The associations of MOK expression with SBP and DBP 
were further replicated in the Framingham Heart Study 
(P=1.02×10−5 and 6.11×10−4, respectively; Table 2). We did 
not identify any signals surviving multiple testing for DBP 
in the Finnish Twin Cohort.
Out of the 40 genes of which their expression levels were 
previously reported to be associated with BP, 12 genes could 
be replicated with consistent direction of effects and FDR 
<0.05 in our twin cohort. Table 3 lists the association of these 
12 genes with both SBP and DBP in our cohort, although 
the original transcriptome-wide signals for certain genes 
were reported only for SBP (TAGLN2 and TAGAP) or DBP 
(S100A10). The higher expression levels of these 12 genes 
were associated with higher BP levels.
A
B
Figure. A, Path diagram for univariate structural equation model. 
The observed phenotypes (P) for cotwins are shown in squares, 
and latent factors are shown in circles. Correlations between 
genetic factors (A) are 1 in monozygotic (MZ) twin pairs and 0.5 
in dizygotic (DZ) twin pairs. Correlations between common (or 
shared) environmental factors (C) are 1 for MZ/DZ twin pairs. 
Unique environmental factors (E) are always uncorrelated. 
Var A C EP V V V( ) = + + ; Cov MZ A C( ) = +V V ; Cov DZ A C( ) = +0 5. V V ;  
h V V V V2 = + +( )A A C E . B, Path diagram for bivariate structural 
equation model (Cholesky model). The 2 phenotypes observed 
(P1 and P2) for cotwins are shown in squares, and latent factors 
are shown in circles. Correlations of the same phenotype 
between genetic factors (A1) are 1 in MZ twin pairs and 0.5 in DZ 
twin pairs. The path of genetic factors between 2 phenotypes 
is a21. Correlations between common (or shared) environmental 
factors (C) are 1 for MZ/DZ twin pairs. The path of common 
environmental factors between 2 phenotypes is c21. Unique 
environmental factors (E) are always uncorrelated. The path of 
unique environmental factors between 2 phenotypes is e21.
Table 1. General Characteristics of the Participants
Variables Overall MZ DZ
N 391 236 155
Age, y, mean (SD) 62.3 (3.8) 61.7 (3.6) 63.2 (3.9)




SBP, mm Hg, mean 
(SD)*
150.2 (18.6) 150.8 (17.9) 149.2 (19.7)
DBP, mm Hg, mean 
(SD)*
87.8 (11.0) 89.0 (11.1) 86.0 (10.7)
DBP indicates diastolic blood pressure; DZ, dizygotic; MZ, monozygotic; and 
SBP, systolic blood pressure.
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Twin correlations for the gene expression levels of the 
newly identified gene (MOK) and the 12 previously reported 
genes are shown in Table 4. With the exception of MYADM 
and TIPARP (TCDD-inducible poly[ADP-ribose] polymerase), 
twin correlations in monozygotic twin pairs were larger than 
those in dizygotic twin pairs, indicating genetic influences. For 
the expression of 7 genes including CRIP1, F12, LMNA, MOK, 
S100A10, TAGAP, and TSC22D3, the best fitting models are 
AE models, with heritability estimates ranging from 0.27 to 
0.65. The remaining part of the variation for the expression of 
these 7 genes is explained by environmental influences that are 
unique to the individual. For the expression of MYADM, the 
best fitting model is the CE model, with the familiar aggregation 
best explained by the shared environmental factor that explains 
47% of the expression variation of the MYADM gene. For the 
expression of the other 5 genes including CD97 (cluster of dif-
ferentiation 97), SLC31A2, TAGLN2, TIPARP, and TPPP3, the 
best fitting models are ACE models. For these genes, the model 
assuming either the absence of A component or absence of C 
component fitted the data well, but the model assuming the 
absence of both components fitted the data significantly worse. 
This indicates that the expression of these genes did show famil-
ial aggregation, either because of genetic or because of shared 
environment influences, and their variations in the population 
could not be explained by unique environmental effects alone.
Next, we estimated the relative contributions of genetic 
and environmental factors to the association between gene 
expressions and BP. Because of the fact that the AE model has 
generally been the best fitting model in previous twin stud-
ies of BP,2,16 which was again confirmed in the current study 
(heritability was 45% for SBP and 40% for DBP, respec-
tively), the bivariate modeling was only conducted on those 
genes with expression levels determined by ACE or AE mod-
els. The results are listed in Table 5. For the association of 
MOK expression with SBP, both a21 and e21 could not be 
set to 0, indicating the phenotypic correlation is determined 
by both shared genetic factors and shared unique environment 
with common genetic factors accounting for 53% of the phe-
notypic correlation. For the association of LMNA, SLC31A2, 
and TSC22D3, expression with BP and the association of 
TAGLN2 expression with SBP, a21 could but e21 could not 
be set to 0, indicating the phenotypic correlation is completely 
determined by shared unique environmental factors. On the 
contrary, the phenotypic correlations of CD97, TIPARP, and 
TPPP3 expression with both SBP and DBP were completely 
determined by shared genetic factors. For the associations of 
the other gene expressions with BP, the model assuming either 
the absence of a21 component or e21 component fitted the 
data well, but the model assuming the absence of both com-
ponents fitted the data significantly worse, indicating a larger 
Table 2. Gene With Expression Level Associated With SBP and DBP
Probe ID Gene Chromosome Trait
Finland Twin Cohort Framingham Heart Study
β SE P Value FDR β SE P Value
ILMN_1745282 MOK* 14 SBP 2.67E-03 4.75E-04 7.16E-08 1.40E-03 8.16E-04 1.85E-04 1.02E-05
DBP 3.58E-03 8.00E-04 1.34E-05 1.74E-01 9.56E-04 2.79E-04 6.11E-04
DBP indicates diastolic blood pressure; FDR, false-discovery rate; MOK, MAPK/MAK/MRK overlapping kinase; and SBP, systolic blood pressure.
*Trans ID 3580234 in Framingham Heart Study, annotated using the Affymetrix annotation file from Netaffx (www.netaffx.com, HuEx-1_0-
st-v2.na29.hg18.probeset.csv).5





Association With SBP Association With DBP
β SE P Value FDR β SE P Value FDR
ILMN_2413508 CD97 SBP/DBP 2.97E−03 8.58E−04 6.75E−04 1.35E−03 3.93E−03 1.43E−03 6.76E−03 7.38E−03
ILMN_1656920 CRIP1 SBP/DBP 2.71E−03 1.01E−03 8.22E−03 8.22E−03 4.63E−03 1.69E−03 6.58E−03 7.38E−03
ILMN_1671766 F12 SBP 1.52E−03 5.60E−04 7.07E−03 7.72E−03 1.59E−03 9.37E−04 9.12E−02 9.12E−02
ILMN_1696749 LMNA SBP/DBP 2.25E−03 6.04E−04 2.57E−04 6.17E−04 4.36E−03 9.89E−04 1.78E−05 2.14E−04
ILMN_2308849 MYADM SBP/DBP 3.80E−03 8.95E−04 3.37E−05 2.02E−04 4.70E−03 1.50E−03 1.96E−03 3.69E−03
ILMN_2046730 S100A10 DBP 1.95E−03 6.62E−04 3.59E−03 4.78E−03 3.11E−03 1.11E−03 5.61E−03 7.38E−03
ILMN_1758938 SLC31A2 SBP/DBP 4.65E−03 1.00E−03 6.75E−06 8.10E−05 5.58E−03 1.70E−03 1.22E−03 3.65E−03
ILMN_1676408 TAGAP SBP 3.91E−03 1.39E−03 5.34E−03 6.41E−03 7.82E−03 2.28E−03 7.34E−04 2.93E−03
ILMN_2090105 TAGLN2 SBP 3.27E−03 8.56E−04 1.82E−04 5.45E−04 4.20E−03 1.43E−03 3.82E−03 5.72E−03
ILMN_1765578 TIPARP SBP/DBP 2.09E−03 6.73E−04 2.17E−03 3.26E−03 3.48E−03 1.12E−03 2.15E−03 3.69E−03
ILMN_1797744 TPPP3 SBP/DBP 2.03E−03 5.15E−04 1.17E−04 4.67E−04 3.27E−03 8.63E−04 2.03E−04 1.22E−03
ILMN_2276952 TSC22D3 SBP/DBP 3.92E−03 1.17E−03 9.33E−04 1.60E−03 6.16E−03 1.96E−03 1.94E−03 3.69E−03
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sample size is needed to increase the power to distinguish the 
relative contributions of genetic and environmental factors to 
the observed phenotypic correlations.
The pathway analyses yielded significant (FDR <0.05) 
enrichment of 16 KEGG and gene ontology biology process 
pathways for SBP-related gene expression changes and 18 
for DBP-related gene expression changes (with 10 pathways 
overlapped between SBP and DBP) in peripheral leukocytes 
(Table S1 in the online-only Data Supplement). These path-
ways represent processes involved in inflammatory pathways 
(eg, antigen processing and presentation, innate immune 
response, defense response to virus, defense response to other 
organism, regulation of type I interferon, and mediated signal-
ing pathway) and autoimmune response (eg, systemic lupus 
erythematosus, type 1 diabetes mellitus, allograft rejection, 
graft versus host disease, and autoimmune thyroid disease).
Discussion
In this study of adult twins, we identified one more gene 
with its expression level associated with BP and replicated 
12 previously identified signals. The newly identified signal 
is MOK gene, which is also known as RAGE-1 (renal tumor 
antigen-1). It was first identified in a renal carcinoma cell 
line17 and has been considered as a tumor-associated antigen 
for its wide expression in various tumors including renal 
carcinoma, melanoma, head and neck cancer, mesotheli-
oma, hepatocellular carcinoma, and leukemia. Later studies 
found that it was also widely expressed in the cytoplasm 
of normal tissues including blood leukocytes.18 Although it 
is suspected that the signaling kinase that belongs to the 
MAPK (mitogen-activated kinase-like protein) superfam-
ily may have important biological functions in different 
physiological processes and in disease, its biological roles 
are still largely unknown. We did not find literature support 
for a direct role of MOK in BP regulation. On the basis of the 
findings by Oehlrich et al19 that MOK could be recognized 
by cytotoxic T lymphocytes to induce immune response and 
its participation in the inflammation response in microglia 
by extracellular stimulation,20 we speculate that MOK may 
participate in BP regulation through inflammation pathway, 
a mechanism that has been implicated in the development 
of hypertension. Further experimental validation is needed.
As opposed to the instructions encoded in the genome 
sequence, actual gene expression (ie, the transcriptome) is tis-
sue specific. The study of the transcriptome in disease requires 
focusing on the specific tissues involved in the pathogenesis 
of this disease. In addition to vasculature, kidney, adrenals, 
and central nervous system, which have long been implicated 
in the regulation of BP, recent evidence has also pointed to the 
involvement of oxidative stress and low-grade inflammation 
in the pathophysiology of hypertension and suggests that the 
immune system might be the missing mechanism that links 
these various organs.21 Both our study and the study from 
Huan et al5 obtained transcriptome-wide gene expression data 
from peripheral leukocytes, and the functional analysis of the 
differentially expressed BP genes from both studies yielded 
significant enrichment of pathways representing processes 
involved in inflammation and immune response, providing 
another strong piece of evidence supporting the involvement 
of inflammation pathways in the pathogenesis of hyperten-
sion. One previous study10 conducted a transcriptome profil-
ing on kidney and identified 14 differentially expressed genes 
in renal medulla and 46 differentially expressed genes in renal 
cortex between 15 hypertensive patients and 7 normotensive 






MZ DZ a2 c2 e2
ILMN_2413508 CD97 0.48 0.34 ACE 0.34 (0.00–0.612) 0.16 (0.00–0.49) 0.50 (0.39–0.65)
ILMN_1656920 CRIP1 0.46 0.24 AE 0.50 (0.35–0.62) … 0.50 (0.38–0.65)
ILMN_1671766 F12 0.53 0.36 AE 0.55 (0.41–0.65) … 0.45 (0.35–0.58)
ILMN_1696749 LMNA 0.58 0.37 AE 0.61 (0.49–0.70) … 0.39 (0.30–0.51)
ILMN_1745282 MOK 0.52 0.26 AE 0.53 (0.40–0.64) … 0.47 (0.36–0.60)
ILMN_2308849 MYADM 0.47 0.48 CE … 0.47 (0.35–0.57) 0.53 (0.42–0.64)
ILMN_2046730 S100A10 0.39 0.13 AE 0.39 (0.22–0.54) … 0.61 (0.46–0.78)
ILMN_1758938 SLC31A2 0.36 0.33 ACE 0.08 (0.00–0.48) 0.28 (0.00–0.45) 0.64 (0.50–0.79)
ILMN_1676408 TAGAP 0.67 0.42 AE 0.65 (0.55–0.72) … 0.35 (0.27–0.45)
ILMN_2090105 TAGLN2 0.42 0.26 ACE 0.36 (0.00–0.56) 0.07 (0.00–0.43) 0.57 (0.44–0.73)
ILMN_1765578 TIPARP 0.40 0.41 ACE 0.06 (0.00–0.52) 0.67 (0.00–0.52) 0.57 (0.44–0.71)
ILMN_1797744 TPPP3 0.30 0.19 ACE 0.26 (0.00–0.47) 0.06 (0.00–0.38) 0.67 (0.52–0.85)
ILMN_2276952 TSC22D3 0.28 0.11 AE 0.27 (0.10–0.41) … 0.73 (0.58–0.90)
CD97 indicates cluster of differentiation 97; DBP, diastolic blood pressure; DZ, dizygotic; MOK, MAPK/MAK/MRK overlapping kinase; MZ, 
monozygotic; SBP, systolic blood pressure; and TIPAPRP, TCDD-inducible poly(ADP-ribose) polymerase.
*A means additive genetic factor; C means common environmental factor; and E means unique environmental factor.
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controls. Out of these 60 genes, the expression data of 48 
are available from the Illumina HumanHT-12 v4 Expression 
BeadChip. However, none of the associations observed in 
renal tissue could be replicated in the current study using 
peripheral leukocytes. In addition to the difference in tis-
sues, this previous study was based on a small sample size 
and lacked a replication cohort. Nevertheless, we think that 
using similar approaches (large discovery panel plus replica-
tion) in tissues such as the kidney, which are potentially more 
relevant for BP other than peripheral leukocytes (ie, the most 
accessible cells), is a promising approach and may yield addi-
tional differentially expressed BP signature genes.
Another difference between the transcriptome and the 
genome is the plasticity of the transcriptome, that is, the find-
ings may reflect the consequence rather than the cause of the 
disease. Theoretically, the cross-sectional association between 
BP and gene expression observed in the current study and the 
previous study can be explained in 4 ways. First, higher BP 
induces the changes in gene expression. Second, changes in 
gene expression induce higher BP. Third, the effect can be 
bidirectional. The cellular processes underlying BP regula-
tion may change gene expression, whereas the latter or its 
downstream molecular products, in turn, may increase the risk 
of hypertension. Fourth, there could be a underlying factor 
that influences both BP levels and gene expressions profiles. 
The twin design of the current study allowed us to explore 
the last explanation. We first quantified the genetic and envi-
ronmental sources of the variations of the 13 (1 novel and 12 
known) BP-related gene expression signatures and observed 
that genetic factors contributed to the variance in expression 
of 12 out of the 13 genes, with the exception of MYADM. The 
heritability estimates of the 12 genes ranged from 6% to 65%. 
A genetic contribution was not identified for MYADM. The 
familial aggregation of its expression level was mainly deter-
mined by shared environmental factors. This is not uncom-
mon, and a previous study6 has shown that as much as 32% 
of transcripts from human lymphoblastoid cell lines have a 
shared environmental component that explain >30% of the 
total variance. Because the previous twin studies2,16 and our 
current study did not find evidence for influence of shared 
environmental factors on BP variation, we examined the com-
mon pathology hypothesis for BP and the 12 genes (CD97, 
CRIP1, F12, LMNA, MOK, S100A10, SLC31A2, TAGAP, 
TAGLN2, TIPARP, TPPP3, and TSC22D3) with their expres-
sion variation determined at least partially by genetic fac-
tors. Significant genetic correlations were observed between 
SBP and MOK expression, as well as SBP/DBP and CD97, 
TIPARP, and TPPP3 gene expression. Up to 53% of the phe-
notypic association between SBP and MOK gene expression 
can be explained by common genetic factors, whereas this 
Table 5. Best Fitting Models of the Bivariate SEM Analysis









ILMN_2413508 CD97 SBP a21≠0 0.39 (0.18 to 0.59) … 1.00 …
ILMN_2413508 CD97 DBP a21≠0 0.34 (0.12 to 0.56) … 1.00 …
ILMN_1656920 CRIP1 SBP a21≠0/e21≠0‡ 0.22 (−0.26 to 0.98) 0.06 (−0.11 to 0.23) 0.77 0.23
ILMN_1656920 CRIP1 DBP a21≠0/e21≠0‡ 0.28 (0.00 to 0.54) 0.05 (−0.11 to 0.22) 0.80 0.20
ILMN_1671766 F12 SBP a21≠0/e21≠0‡ 0.015 (−0.09 to 0.40) 0.07 (−0.10 to 0.24) 0.69 0.31
ILMN_1696749 LMNA SBP e21≠0 … 0.24 (0.09 to 0.37) … 1.00
ILMN_1696749 LMNA DBP e21≠0 … 0.28 (0.14 to 0.41) … 1.00
ILMN_1745282 MOK SBP a21≠0 and e21≠0 0.27 (0.01 to 0.49) 0.26 (0.09 to 0.41) 0.52 0.48
ILMN_2046730 S100A10 DBP a21≠0/e21≠0‡ 0.14 (−0.20 to 0.45) 0.07 (−0.10 to 0.24) 0.56 0.44
ILMN_1758938 SLC31A2 SBP e21≠0 … 0.27 (0.14 to 0.39) … 1.00
ILMN_1758938 SLC31A2 DBP e21≠0 … 0.17 (0.03 to 0.30) … 1.00
ILMN_1676408 TAGAP SBP a21≠0/e21≠0‡ 0.08 (−1.00 to 1.00) 0.17 (−0.01 to 0.33) 0.36 0.64
ILMN_2090105 TAGLN2 SBP e21≠0 … 0.29 (0.15 to 0.41) … 1.00
ILMN_1765578 TIPARP SBP a21≠0 0.46 (0.20 to 0.67) … 1.00 …
ILMN_1765578 TIPARP DBP a21≠0 0.40 (0.18 to 0.66) … 1.00 …
ILMN_1797744 TPPP3 SBP a21≠0 0.41 (0.18 to 0.65) … 1.00 …
ILMN_1797744 TPPP3 DBP a21≠0 0.45 (0.21 to 0.69) … 1.00 …
ILMN_2276952 TSC22D3 SBP e21≠0 … 0.22 (0.09 to 0.34) … 1.00
ILMN_2276952 TSC22D3 DBP e21≠0 … 0.21 (0.08 to 0.33) … 1.00
CD97 indicates cluster of differentiation 97; DBP, diastolic blood pressure; MOK, MAPK/MAK/MRK overlapping kinase; and SBP, systolic blood pressure.
*r
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was 100% for CD97, TIPARP, and TPPP3 with both SBP and 
DBP. These results indicate that shared genes did contribute 
substantially to the association of BP with expression of cer-
tain genes (CD97, MOK, TIPARP, and TPP3 [tubulin polym-
erization-promoting protein family member 3]).
The identification of common genetic effects account-
ing for the association between BP and gene expression has 
important implications for gene-finding studies. In the current 
gene-finding efforts for BP, univariate analysis has been con-
ducted with BP as the phenotype of interest. Even with the 
most recent findings from 3 large-scale genome-wide asso-
ciation studies22–24 in >300 000 subjects, which have expanded 
the list of genetic loci for BP to almost 400, adding all the loci 
together only explains 3% to 4% of BP variance, although the 
heritability calculated from all genotyped and imputed single-
nucleotide polymorphisms is ≈17%.25 With the identification 
of common genetic effects, bivariate analysis with both BP 
and gene expression as the phenotypes of interests can be 
applied to identify the shared genetic variants. Such an analy-
sis strategy might not only help to identify more BP-related 
loci but also has the potential to shed light on the underlying 
mechanisms.
Our study has several limitations that need to be recog-
nized. First, the study was designed to have an oversampling 
of twins from pairs discordant for essential hypertension. 
However, the univariate twin modeling on BP observed 
results similar to previous twin studies with twins recruited 
from the general population, indicating this specific design 
did not lead to large biases in heritability estimates. Second, 
our study is cross-sectional, thus limited in the ability to dis-
cern the temporal order between BP and gene expression. 
However, the identification of common genetic precursors 
for BP and expression of CD97, MOK, TIPARP, and TPPP3 
genes renders a cause–effect relationship for these genes 
unlikely. Third, the study only included white adults, thus one 
should be cautious extending our results to other ethnic or 
age groups. Fourth, although this study included almost 400 
twins, an even larger sample size is required to tease out the 
relative contribution of genetic or environmental factor to the 
associations of BP with gene expression. Fifth, transcriptome 
data were obtained using traditional chip technology in this 
study. In comparison with the current state-of-the-art RNA-
seq approach, some low abundance transcripts might have 
been missed.
In conclusion, we identified one more gene with its 
expression level associated with BP and replicated several 
previously identified signals. Our study further provides 
new insights into the genetic and environmental sources of 
BP-related gene expression signatures and their associa-
tions with BP. The identification of common genetic effects 
between BP and gene expression of CD97, MOK, TIPARP, 
and TPPP3 will aid in future BP gene-finding efforts and may 
ultimately point toward more effective prevention and treat-
ment of hypertension.
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What Is New?
•	 Identify one more gene with its expression associated with blood pres-
sure.
•	Discover that genetic factors contribute to the expression variations of 12 
blood pressure (BP)–associated genes.
•	Discover that common genetic effects account for the observed associa-
tions between BP and the expression of 4 genes.
What Is Relevant?
•	Discovery of common genetic factors may point toward a common 
pathogenic pathway and has the potential to improve our understanding 
of the molecular mechanisms underlying BP regulation.
Summary
In this study of adult twins, 391 twins were recruited from the 
Finnish Twin Cohort. Their gene expression data in peripheral 
leukocytes were obtained using Illumina HT12 V4 array. Their 
comprehensive physical examination and health history as well as 
blood pressure were measured during clinical visit. Linear mixed 
model was used to identify the differentially expressed genes 
associated with blood pressure. Univariate structural equation 
modeling and bivariate structural equation modeling were used 
to further investigate to what extent the genetic factor and envi-
ronmental factor influence gene expression and blood pressure. 
Our study identified one more gene (MOK [MAPK/MAK/MRK over-
lapping kinase]) with its expression level associated with BP and 
replicated 12 previously identified signals. Univariate twin mod-
eling showed that genetic factors contributed to the expression 
variations of 12 genes with heritability estimates ranging from 6% 
to 65%. Bivariate twin modeling showed that 53% of the pheno-
typic association between systolic BP and MOK expression, and 
100% of the phenotypic association of systolic and diastolic BP 
with CD97 (cluster of differentiation 97), TIPARP (TCDD-inducible 
poly[ADP-ribose] polymerase), and TPPP3 expression could be ex-
plained by genetic factors shared in common. Our study provides 
new insights into the genetic and environmental sources of BP-





 http://ahajournals.org by on August 21, 2018
